Actively Recruiting

Phase Not Applicable
Age: 18Years - 75Years
All Genders
ID06221254

Israeli IBD Research Nucleus (IIRN) Consortium: COBMINDEX Goes Forward- A Smartphone Application for Added Psychological Wellbeing in Crohn's Disease

Led by Soroka University Medical Center · Updated on 2026-04-30

200

Participants Needed

4

Research Sites

8 weeks

Total Duration

On this page

Sponsors

S

Soroka University Medical Center

Lead Sponsor

T

The Leona M. and Harry B. Helmsley Charitable Trust

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are evaluating the use of the COBMINDEX smartphone application to reduce psychological stress, fatigue, and pain in adults with Crohn's disease. The study aims to improve patients' well-being, quality of life, coping skills, immunological profile, and intestinal microbiome. This is an interventional trial involving behavioral therapy techniques. Participants will be divided into two groups of 100 each. One group will learn and practice COBMINDEX techniques from a human therapist over three months, while the other group will use the digital COBMINDEX application guided by a digital therapist. Following this initial period, both groups will continue practicing daily with the application for an additional nine months. During the 12-month study, patients will be assessed daily for stress, pain, fatigue, and well-being. Frequent evaluations will include medical, psychological, and immunological status assessments. Researchers will also monitor adverse events and concomitant medications. The primary outcome is the effectiveness of the application compared to the human therapist over 12 months.

CONDITIONS

Brief Title

A Smartphone Application for Added Psychological Wellbeing in Crohn's Disease

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Willingness to participate and signed informed consent
  • Hebrew-speaking
  • Age 18-75
  • Proven diagnosis of Crohn's disease, at least 3 months post-diagnosis
  • Stable medical treatment for the last 3 months
  • Any Harvey Bradshaw Index score
  • Ability to operate a smartphone and cellular application
Not Eligible

You will not qualify if you...

  • Diagnosis of ulcerative colitis or unclassified inflammatory bowel disease
  • Planned surgery for Crohn's disease
  • Surgery for Crohn's disease (excluding drainage of perianal abscess) in the last 3 months
  • Psychiatric disease (schizophrenia, major depression or bipolar disorder)
  • Alcohol or drug dependency (stable medical use of cannabinoids will be allowed)
  • Pregnancy or planned pregnancy during study period
  • Clinically significant comorbidity
  • Former participation in COBMINDEX trials

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Outpatient Treatment

Duration - 3 months

Participants learn cognitive, behavioral, and mindfulness-based stress reduction techniques either from a human therapist or via a digital application, practicing daily exercises during this period.

Regular daily practice with assessments

Outpatient Treatment

Duration - 9 months

Participants continue daily practice using the COBMINDEX application with permissions according to their group assignment, with ongoing assessment of stress, pain, fatigue, well-being, and medical, psychological, and immunological status.

Daily assessments throughout this period

Trial Site Locations

Total: 4 locations

1

Soroka University Medical Center

Beersheba, Israel, 8410101

Actively Recruiting

2

Rambam Health Care Campus i

Haifa, Israel, 3109601

Not Yet Recruiting

3

Belinson Medical Center

Petah Tikva, Israel, 4941492

Not Yet Recruiting

4

Sheba Medical Center

Ramat Gan, Israel, 5266202

Not Yet Recruiting

Loading map...

Research Team

D

Doron Schwartz, MD

S

Shmuel Odes, MD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

Follow-up Study to Evaluate the Safety of ALLO-ASC-CD in the...

Crohn Disease

Actively Recruiting

2 locations

A Master Protocol for Phase 2, Randomized, Controlled Studie...

Colitis, Ulcerative

Actively Recruiting

72 locations

Pilot Study for Imaging the Lower Gastrointestinal Tract Usi...

Lynch Syndrome

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here